Loading
NNC0487-0111 / Obesity / Overweight · Phase 3 Trial
ClinicalTrials.gov · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
AMAZE 2 is a Phase 3 randomized controlled trial comparing the investigational agent NNC0487-0111 to placebo in participants with excess body weight and type 2 diabetes, with a primary endpoint of relative change in body weight at 84 weeks. No results have been posted in this registry record; the trial is actively recruiting and remains in progress.
Phase 3, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Diabetes Mellitus, Overweight, Obesity; age from 18 Years. Intervention: NNC0487-0111 dose level 1; NNC0487-0111 dose level 2; NNC0487-0111 dose level 3; NNC0487-0111 dose level 4. Compared with: Placebo — Placebo Comparator. n = 630. 74 sites across 10 countries.
AMAZE 2 is a Phase 3 randomized controlled trial comparing the investigational agent NNC0487-0111 to placebo in participants with excess body weight and type 2 diabetes, with a primary endpoint of relative change in body weight at 84 weeks. No results have been posted in this registry record; the trial is actively recruiting and remains in progress.
No efficacy or safety data reported; outcome measures are not yet available.
The source did not state who this applies to in practice.
This is a Phase 3 trial registration with no results posted; the study is actively recruiting and outcome data are not yet available, making it an early-stage report of a planned intervention.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07533175). This is a study registration, not published results. Lead sponsor: Novo Nordisk A/S. Recruitment status: RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 630 participants (ESTIMATED). Conditions: Diabetes Mellitus, Overweight, Obesity. Interventions: DRUG: NNC0487-0111; DRUG: Placebo (matched to NNC0487-0111). Primary outcome measures: Relative change in body weight , From baseline (week 0) to (week 84). Brief summary: The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.